Regeneron Pharmaceuticals Inc (REGN) : Premier Asset Managment reduced its stake in Regeneron Pharmaceuticals Inc by 0.39% during the most recent quarter end. The investment management company now holds a total of 36,575 shares of Regeneron Pharmaceuticals Inc which is valued at $14,070,403 after selling 145 shares in Regeneron Pharmaceuticals Inc , the firm said in a disclosure report filed with the SEC on Jul 18, 2016.Regeneron Pharmaceuticals Inc makes up approximately 3.44% of Premier Asset Managment’s portfolio.
Other Hedge Funds, Including , Braver Wealth Management sold out all of its stake in REGN during the most recent quarter. The investment firm sold 1,400 shares of REGN which is valued $510,300.Exxonmobil Investment Management Inc Tx boosted its stake in REGN in the latest quarter, The investment management firm added 1,180 additional shares and now holds a total of 20,190 shares of Regeneron Pharmaceuticals Inc which is valued at $7,638,887. Regeneron Pharmaceuticals Inc makes up approx 0.16% of Exxonmobil Investment Management Inc Tx’s portfolio.Chevy Chase Trust Holdings boosted its stake in REGN in the latest quarter, The investment management firm added 833 additional shares and now holds a total of 72,851 shares of Regeneron Pharmaceuticals Inc which is valued at $27,563,176. Regeneron Pharmaceuticals Inc makes up approx 0.15% of Chevy Chase Trust Holdings’s portfolio.Bnp Paribas Arbitrage Sa reduced its stake in REGN by selling 31,483 shares or 43.38% in the most recent quarter. The Hedge Fund company now holds 41,092 shares of REGN which is valued at $15,547,158. Regeneron Pharmaceuticals Inc makes up approx 0.07% of Bnp Paribas Arbitrage Sa’s portfolio.
Regeneron Pharmaceuticals Inc opened for trading at $377.48 and hit $386.97 on the upside on Wednesday, eventually ending the session at $384.7, with a gain of 2.00% or 7.55 points. The heightened volatility saw the trading volume jump to 6,31,344 shares. Company has a market cap of $40,424 M.
On the company’s financial health, Regeneron Pharmaceuticals Inc reported $2.57 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on May 5, 2016. Analyst had a consensus of $2.55. The company had revenue of $1201.00 million for the quarter, compared to analysts expectations of $1178.39 million. The company’s revenue was up 38.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.88 EPS.
Many Wall Street Analysts have commented on Regeneron Pharmaceuticals Inc. Regeneron Pharmaceuticals Inc was Initiated by Bernstein to “Outperform” on Jun 29, 2016. Regeneron Pharmaceuticals Inc was Downgraded by Wells Fargo to ” Market Perform” on Apr 20, 2016.
Regeneron Pharmaceuticals Inc. is an integrated biopharmaceutical company that discovers invents develops manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases colorectal cancer and a rare inflammatory condition and has product candidates under development in other areas including hypercholesterolemia oncology rheumatoid arthritis (RA) asthma and atopic dermatitis. The Company’s marketed products include EYLEA (aflibercept) injection ZALTRAP (ziv-aflibercept) injection for intravenous infusion and ARCALYST (rilonacept) injection for subcutaneous use. The Company has 17 product candidates in clinical development. Its product candidates consist of two trap-based clinical programs and 15 human monoclonal antibody product candidates. The Company has generated each of the antibodies using its VelocImmune technology.